| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
6 companies
Mary Ann Gray is Director at ACAD, with reported holdings spanning 6 companies. Mary Ann Gray's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.9M at current prices.
Mary Ann Gray's largest disclosed position is in ACAD as Director, worth about $3.1M. The ACAD filings lean toward selling, a net 4,250 shares.
Mary Ann Gray has 59 Form 4 filings on record from January 2015 to June 2026, across 8 companies: Director at Keros Therapeutics (KROS), 2020–2026; Director at RAPT Therapeutics (RAPT), 2019–2026; Director at Compass Therapeutics (CMPX), 2022–2026, and 5 more.
The 87 reported transactions were 45 option or other derivative awards, 17 stock awards, 13 dispositions back to the company and 10 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $149K.
The only open-market sale was 4,250 shares of ACAD at an average $35.00 on January 13, 2015, about $149K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 13, 2015 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 4,250 | $35.00 | $148,750.00 | - |